Trial 0C-18-21


A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Diana Hanna, M.D.
Other Trial Staff:  Yan Ning, D.M., Chi Nguyen, Coordinator, Leila Andres, Coordinator, Nicole Jensen, Coordinator, Anayansi Miloud, D.M., Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Atessa Kiani, Coordinator, Negeen Izadian, Coordinator, Diane Habib, Coordinator, Judy Smith, Coordinator, Stephanie Kim, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.